In this interview, Danny Cabrera, co-founder of BioBots (Philadelphia, PA, USA), discusses the development of biomaterials for 3D printing tissues.
3D bioprinting looks set to have a huge impact on the field of regenerative medicine by allowing the artificial generation of tissues and organs through fabrication of scaffolds and 3D tissues, supporting cell or drug delivery, and so on. However, this requires the development and use of biomaterials that meet the physical, chemical and functional requirements for each use. In this interview, Danny Cabrera, co-founder of BioBots (Philadelphia, PA, USA) discusses the development of biomaterials for 3D printing tissues.
Danny Cabrera started BioBots in 2014, after studying computer science and biology at the University of Pennsylvania (PA, USA). BioBots is empowering people to build with life by helping design and engineer biology to cure disease, eliminate the organ waiting list, revert climate change, and live on other planets. Its first product is the BioBot 1, a 3D bioprinter, and they also sell a variety of bioinks.
- 00:00 — introduction
- 00:30 — founding BioBots
- 01:55 — partners & tissues printed so far
- 03:50 — main materials used for bioprinting
- 07:05 — considerations for development of different types of bioink
- 09:30 — biocompatibility & clinical use
- 10:50 — complexity/tissue-specific biomaterials
- 12:40 — getting printing functional 3D living tissues to the clinic
- 14:30 — final comments